why choose us

First received: November 18, 2022

Clinical Trial: Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Paroxysmal Nocturnal Hemoglobinuria

Study Type: INTERVENTIONAL


Official Title: A Multicenter, Single Arm, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily Iptacopan in Adult PNH Patients Who Have Hb?10 g/dL in Response to Anti-C5 Antibody and Switch to

Brief Summary: The purpose of the study is to find out if iptacopan is effective and safe in adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who switch from their current standard of care treatment (eculizumab or ravulizumab) to study treatment, iptacopan/LNP023.

Read more